Description
ADCC-enhanced Sifalimumab is a non-fucosylated anti-IFNA1 therapeutic biobetter antibody.
Antibody Indication
Rheumatoid arthritis (RA)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IFNA1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IFNA1
Full Name
Interferon Alpha 1
Background
The protein encoded by this gene is produced by macrophages and has antiviral activity. This gene is intronless and the encoded protein is secreted. [provided by RefSeq, Sep 2011]
Alternative Names
Faralimomab; 167816-91-3; IFNA1; interferon, alpha 1; interferon alpha-1/13; IFL; IFN; IFN ALPHA; IFN alpha 1b; IFN alphaD; IFNA13; IFNA@; interferon alpha 1b; leIF D; IFN-alpha 1b; IFN-alpha-1/13; interferon-alpha1; interferon alpha-D; IFN-ALPHA; IFN-alphaD; MGC138207;
Gene ID
3439
UniProt ID
P01562
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IFNA1 include Hepatitis and Viral Infectious Disease.
Related Pathways
Its related pathways are all-trans-Retinoic Acid Mediated Apoptosis and Tuberculosis.
Function
Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.
Post-translational modifications
1.Modification sites at PhosphoSitePlus 2.Modification sites at neXtProt
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Sifalimumab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human IFNA1. Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.
Antibody Indication
Rheumatoid arthritis (RA)
Rheumatoid arthritis (RA)
